Chicago, IL – According to filings with the U.S. Securities and Exchange Commission, Emalex Biosciences is raising $250,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Jeffrey Aronin played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Emalex Biosciences
Emalex Biosciences, LLC is a biopharmaceutical company dedicated to the development of new treatments for rare and orphan neurological conditions. Ecopipam, its first development candidate, is a novel compound that has been studied as a potential treatment for many central nervous system (CNS) disorders, including pediatric Tourette Syndrome. The latter is a childhood-onset neurodevelopmental condition characterized by motor and vocal tics for which very few safe and effective therapies exist.

To learn more about Emalex Biosciences, visit http://www.emalexbiosciences.com/

Contact:
Jeffrey Aronin, Chief Executive Officer
312-847-1340

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved